Authorization

AstraZeneca: FDA Approves New Dosing Option For Imfinzi - Quick Facts

(RTTNews) - AstraZeneca (AZN.L, AZN) said Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer. The decision follows the Priority Review granted by the FDA in August 2020.

The company noted that the four-week 1,500mg fixed-dosing option for Imfinzi is also under regulatory review in several other countries, including in the EU where the new dosing option was granted accelerated assessment.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2021    »
ПнВтСрЧтПтСбВс
 123
45678910
11121314151617
18192021222324
25262728293031